INTECH Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

INTECH Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Buy	12,056 +58	+0.5%	+$645	﹤0.01%	1825
2026 Q1	$112K	Sell	11,998 -7,997	-40%	-$72.1K	﹤0.01%	1874
2025 Q4	$179K	Sell	19,995 -900	-4%	-$8.51K	﹤0.01%	2022
2025 Q3	$199K	Sell	20,895 -4,697	-18%	-$47.1K	﹤0.01%	2071
2025 Q2	$225K	Hold	25,592	–	–	﹤0.01%	2027
2025 Q1	$192K	Buy	25,592 +12,345	+93%	+$98.1K	﹤0.01%	2108
2024 Q4	$110K	Sell	13,247 -501	-4%	-$4.28K	﹤0.01%	2192
2024 Q3	$95.4K	Buy	+13,748	New	+$93.3K	﹤0.01%	1892

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

INTECH Investment Management's ZVRA Position: Q2 2026 in Review

INTECH Investment Management increased its Zevra Therapeutics (ZVRA) stake by 0.48% in Q2 2026, buying an estimated $645 and bringing the position to 12,056 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1825.

INTECH Investment Management first reported a position in ZVRA in Q3 2024 and has held it in 8 quarters since. The position peaked at $225K in Q2 2025. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

INTECH Investment Management held 12,056 shares of Zevra Therapeutics worth $173K as of Q2 2026.
INTECH Investment Management bought 58 Zevra Therapeutics shares in Q2 2026, an estimated $645.
Zevra Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1825 holding.
INTECH Investment Management first reported a position in Zevra Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Zevra Therapeutics position peaked at $225K in Q2 2025.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.